Факторы, влияющие на агрессивное течение туберкулезной инфекции (обзор)

Литература:
1. Schami A, Islam MN, Belisle JT, et al. Drug-resistant strains of Mycobacterium tuberculosis: cell envelope profiles and interactions with the host. Front Cell Infect Microbiol. 2023;13:1274175. DOI:10.3389/fcimb.2023.1274175
2. Лушина О. В., Павлова М. В., Арчакова Л.Т. и др. Успешное лечение туберкулеза легких с широкой лекарственной устойчивостью микобактерий у пациентки с онкологической патологией. Туберкулез и социально-значимые заболевания. 2020;(3):63-7. EDN YQJKZL
3. Zhuang L, Yang L, Li L, et al. Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention. MedComm (2020). 2024;5(1):e419. DOI:10.1002/mco.419
4. Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol. 2022;12:943545. DOI:10.3389/fcimb.2022.943545
5. Вишневский Б. И., Яблонский П. К. Персистенция Mycobacterium tuberculosis — основа латентного туберкулеза (обзор литературы). Медицинский альянс. 2020;8(2): 14-20. EDN LBYAXH
6. Krasilnikov I, Lehnherr-llyina Т, Djonovic М, et al. Cracking the antigeniccode of mycobacteria: CFP-10/ESAT-6 tuberculosis skin test and misleading results. J Clin Tuberc Other Myco-bact Dis. 2024;36:100436. DOI:10.1016/j.jctube.2024
7. Wang H, Jiang H, Teles RMB, et al. Cellular, molecular, and immunological characteristics of langhans multinucleated giant cells programmed by IL-15. J Invest Dermatol. 2020;140 (9):1824-36.e7. DOI:10.1016/j.jid.2020.01.026
8. Urbanowski ME, Ordonez AA, Ruiz-Bedoya CA, et al. Cavitary tuberculosis: the gateway of disease transmission. Lancet Infect Dis. 2020;20 (6):e117-28. DOI:10.1016/S1473-3099 (20)30148-1
9. Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol. 2022;20(12):750-66. DOI:10.1038/s41579-022-00763-4
10. Su H, Weng S, Luo L, et al. Mycobacterium tuberculosis hijacks host macrophages-derived interleukin 16 to block phagolysosome maturation for enhancing intracellular growth. Emerg Microbes Infect. 2024;13(1):2322663. DOI:10.1080/222 21751.2024.2322663
11. Getahun M, Blumberg HM.Ameni G, et al. Minimum inhibitory concentrations of rifampin and isoniazid among multidrug and isoniazid resistant Mycobacterium tuberculosis in Ethiopia. PLoS One. 2022;17(9):e0274426. DOI:10.1371/journal.pone. 0274426
12. Jacobo-Delgado YM, Rodriguez-Carlos A, Serrano CJ, et al. Mycobacterium tuberculosis cell-wall and antimicrobial pep-tides: A mission impossible? Front Immunol. 2023;14:1194923. DOI:10.3389/fimmu.2023.1194923
13. Amarnath S, Deeb L, Philipose J, et al. Comprehensive review of infectious granulomatous diseases of the gastrointestinal tract. Gastroenterol Res Pract. 2021 ;2021:8167149. DOI:10.1155/2021/81671498 14. Ashenafi S, Brighenti S. Reinventing the human tuberculosis (ТВ) granuloma: Learning from the cancer field. Front Immunol. 2022;13:1059725. DOI:10.3389/fimmu.2022.10 59725
15. Fathima SD, Gururaj N, Sivapathasundharam B, et al. Histopathological significance of necrosis in oral lesions: A review. J Oral Maxillofac Pathol. 2023;27(2):340-7. DOI:10.4103/jomfp. jomfp_39_23
16. Sholeye AR, Williams AA, Loots DT, et al. Tuberculous granuloma: Emerging insights from proteomicsand metabolomics. Front Neurol. 2022;13:804838. DOI:10.3389/fneur. 2022.804838
17. GillerDB, KoroevVV, Kesaev OS, etal. Surgical treatment of cavernous and fibrous-cavernous ТВ in children. Thorac Cardiovasc Surg. 2023;71(1):67-72. DOI:10.1055/s-0042-1754318
18. Zhao X, Cheng Y, Xiong Y, et al. Pulmonary tuberculosis associated acute fibrinous and organizing pneumonia: A case report and literature review. Clin Respir J. 2023;17(6):499-506. DOI:10.1111/crj.13626
19. Vu A, Glassman I, Campbell G, et al. Host cell death and modulation of immune response against Mycobacterium tuberculosis infection. Int J Mol Sci. 2024;25(11):6255. DOI:10.3390/ijms25116255
20. Shi X, Li C, Cheng L, et al. Mycobacterium tuberculosis Rv1324 protein contributes to mycobacterial persistence and causes pathological lung injury in mice by inducing ferroptosis. Microbiol Spectr. 2023;11(1):e0252622. DOI:10.1128/spectrum.02526-22
21. Carabali-lsajarML, Rodriguez-Bejarano OH,AmadoT, et al. Clinical manifestations and immune response to tuberculosis. World J Microbiol Biotechnol. 2023;39(8):206. DOI:10.1007/s11274-023-03636-x
22. Sankar P, Mishra BB. Early innate cell interactions with Mycobacterium tuberculosis in protection and pathology of tuberculosis. Front Immunol. 2023;14:1260859. DOI:10.3389/fimmu.2023.1260859
23. Yuk JM, Kim JK, Kim IS, et al. TNF in human tuberculosis: A double-edged sword. Immune Netw. 2024;24 (1 ):e4. DOI:10.4110/in.2024.24.e4
24. Wen P, Wei M, Han C, et al. Risk factors for tuberculous empyema in pleural tuberculosis patients. Sci Rep. 2019;9 (1 ):19569. DOI:10.1038/S41598-019-56140-4
25. Arliny Y, Yanifitri DB, Utami WA, et al. Case report: Tuberculosis lymphadenitis with systemic lupus erythematosus in a young woman: A case report. F1000Res. 2023;12:763. DOI: 10.12688/fl 000research.135076.2
26. Khan FY Review of literature on disseminated tuberculosis with emphasis on the focused diagnostic workup. J Family Community Med. 2019;26 (2):83-91. DOM 0.4103/jfcm.JFCMJ06J8
27. Chai Q, Lu Z, Liu CH. Host defense mechanisms against Mycobacterium tuberculosis. Cell Mol Life Sci. 2020;77 (10):1859-78. DOI:10.1007/s00018-019-03353-5
28. Reichler MR, Hirsch C, Yuan Y, et al.; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Predictive value of TNF-a, IFN-y, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. ВМС Infect Dis. 2020;20(1):553. DOI:10.1186/s12879-020-05185-2
29. Riyaz Tramboo S, Elkhalifa AME, Quibtiya S, et al. The critical impacts of cytokine storms in respiratory disorders. Heliyon. 2024;10(9):e29769. DOM0.1016/j.heliyon.2024.e29769
30. Anes E, Pires D, Mandal M, et al. ESAT-6 a major virulence factor of Mycobacterium tuberculosis. Biomolecules. 2023;13(6):968. DOM0.3390/biom13060968
31. Ramon-Luing LA, Palacios Y, Ruiz A, et al. Virulence factors of Mycobacterium tuberculosis as modulators of cell death mechanisms. Pathogens. 2023;12(6):839. DOI:10.3390/pathogens12060839
32. Genestet C, Refregier G, Hodille E, et al. Mycobacterium tuberculosis genetic features associated with pulmonary tuberculosis severity. Int J Infect Dis. 2022;125:74-83. DOI:10.1016/j.ijid.2022.10.026
33. MeiYM,Zhang WY, Sun JY, etal. Genomiccharacteristics of Mycobacterium tuberculosis isolates of cutaneous tuberculosis. Front Microbiol. 2023;14:1165916. DOI:10.3389/fmicb.2023.1165916
34. TraoreAN, Rikhotso MC, Mphaphuli MA, etal. Isoniazid and rifampicin resistance-conferring mutations in Mycobacterium tuberculosis isolates from South Africa. Pathogens. 2023;12 (8): 1015. DOI:10.3390/pathogens12081015
35. Cubillos-Angulo JM, Arriaga MB, Melo MGM, et al. Polymorphisms in interferon pathway genes and risk of Mycobacterium tuberculosis infection in contacts of tuberculosis cases in Brazil. Int J Infect Dis. 2020;92:21-8. DOI:10.1016/j.ijid. 2019.12.013
36. Parbhoo T, Mouton JM, Sampson SL. Phenotypic adaptation of Mycobacterium tuberculosis to host-associated stressors that induce persister formation. Front Cell Infect Microbiol. 2022;12:956607. DOM0.3389/fcimb.2022.956607
37. Amaral EP, Vinhaes CL, Oliveira-de-Souza D, et al. The interplay between systemic inflammation, oxidative stress, and tissue remodeling in tuberculosis. Antioxid Redox Signal. 2021 ;34(6):471-485. DOM0.1089/ars.2020.8124.
38. Shaku M, Ealand С, Kana BD. Cell surface biosynthesis and remodeling pathways in mycobacteria reveal new drug targets. Front Cell Infect Microbiol. 2020;10:603382. DOI:10.3389/fcimb.2020.603382
39. MaitraA, MunshiT, Healy J, etal. Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles' heel for the TB-causing pathogen. FEMS Microbiol Rev. 2019;43(5):548-75. DOI:10.1093/femsre/fuz016
40. Sabir N, Hussain T, Mangi MH, et al. Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis. Cell Prolif. 2019;52(4):e12649. DOI:10.1111/cpr.12649
41. Zhai W, Wu F, Zhang Y, et al. The immune escape mechanisms of Mycobacterium tuberculosis. Int J Mol Sci. 2019;20(2):340. DOM0.3390/ijms20020340
42. Li Y, de Macedo Couto R, Pelissari DM, et al. Excess tuberculosis cases and deaths following an economic recession in Brazil: An analysis of nationally representative disease registry data. Lancet Glob Health. 2022;10(10):e1463-72. DOI:10.1016/S2214-109X(22)00320-5
43. Viana PVS, Paiva NS, Villela DAM, et al. Factors associated with death in patients with tuberculosis in Brazil: Competing risks analysis. PLoS One. 2020;15 (10):e0240090. DOI:10.1371/journal.pone.0240090